Dipna Pharmachem share price, P/E, ROE & financials

Dipna Pharmachem (BSE: DPL) had a P/E of 10.5× on 6 Nov 2026, below the industry P/E of 27.6×, and the shares are 78% below their 52-week high. It earns ROCE of 5.2% and ROE of 1.9%, and sales and net profit grew 7.7% and 2.2% a year over 3 years. Debt is 0.21× equity. It is listed on an SME platform with a market cap of ₹11 Cr, ranked 8th of 8 Pharmaceutical Retailers companies by market cap; the shares fell 78% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Mar 2026.How we calculate this

past year

Open: ₹4.30
Day high: ₹4.31
Day low: ₹4.13
Prev. close: ₹4.24
Volume: 42K

Health check

1 good · 5 to check

ReturnsBehind
−78.4% over a year, better than 0 of 7 peers.
Price tagCheaper
P/E 10.5 vs industry 27.6.
GrowthSlow
Sales +7.7%, profit +2.2% a year over 3 years.
ProfitabilityWeak
ROCE 5.2% vs peer median 12.2%.
Balance sheetStretched
Debt 0.21× equity, interest covered 1.6×, Piotroski 2 of 9.
Red flags5 to check
Return on equity is low at 1.9%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Pharmaceutical Retailers

7 listed peers. Screen the industry

Small cap

₹11 Cr, #8 of 8 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Mar 2026: sales ₹134 Cr · profit ₹2 Cr

Market cap: ₹11 Cr; Small cap
P/E: 10.5; Industry 27.6
Price to book: 0.18; Peers 3.47
Dividend yield: 0.00%
ROE: 1.9%; Peers 11.5%
ROCE: 5.2%; Peers 12.2%
Debt to equity: 0.21
EPS (TTM): ₹0.41
OPM (TTM): 3.5%; Net margin 1.8%
Sales growth: −87.3%; Latest quarter vs a year ago
Profit growth: −64.4%; Latest quarter vs a year ago
Price to sales: 0.08

Strengths

P/E of 10.5 against an industry P/E of 27.6.

Risks to check

Return on equity is low at 1.9%.
Quarterly profit down 64.4% on a year ago.
Quarterly sales down 87.3% on a year ago.
78% below its 52-week high.
Interest coverage of only 1.6×.

Derived automatically from reported figures. Not a recommendation.

About Dipna Pharmachem

Dipna Pharmachem Limited imports, trades in, and exports pharmaceutical products primarily in India. It offers industrial chemicals, pharmaceutical raw materials, excipients, solvents, active pharmaceutical ingredients, formulations, and intermediates. The company was incorporated in 2011 and is based in Ahmedabad, India.

Headquarters: Ahmedabad
Sector: Healthcare
ISIN: INE0MC401013
Website: dipnapharmachem.com

Price range

52 weeks

₹3.62₹19.90

Today

₹4.13₹4.31

Avg volume (3M): 59.1K
1-year return: minus 78.4%
From 52-week high: minus 78.3%

Peers · Pharmaceutical Retailers

Compare with peers Screen the whole industry

Company
MEDPLUSMedplus Health Services	604.60	plus 0.66%	7,260	34.3	3.47	12.2%	10.8%	4.2%	14.7%	64.0%	0.00%	minus 25.7%
HEALTHXHealth X Platform	272.55	minus 0.42%	867	–	1.35	−0.2%	0.2%	−4.4%	8.0%	–	0.00%	minus 8.3%
ONEGLOBALOne Global Service Provider	365.45	minus 7.66%	714	9.7	5.06	65.7%	65.3%	19.2%	201.8%	269.3%	0.23%	minus 32.0%
TLLTrident Lifeline	413.75	minus 2.07%	495	21.0	4.22	21.8%	23.6%	22.8%	59.7%	46.8%	0.24%	plus 40.8%
ACHYUTAchyut Healthcare	7.76	plus 4.86%	187	776.0	5.45	1.1%	1.0%	2.2%	62.6%	10.9%	0.00%	plus 28.7%
MAITRIMaitri Enterprises	31.20	plus 0.32%	14	37.6	2.61	19.9%	12.1%	5.4%	35.8%	–	0.00%	minus 11.4%
MULLERMuller & Phipps (India)	193.80	plus 3.11%	12	–	−5.82	1.8%	–	−17.2%	12.9%	–	0.00%	minus 23.9%
DPLDipna Pharmachem	4.31	plus 1.65%	11	10.5	0.18	5.2%	5.2%	21.2%	7.7%	2.2%	0.00%	minus 78.4%
Median of 7 peers	–	0.32%	495	34.3	3.47	12.2%	11.5%	4.2%	35.8%	55.4%	0.00%	−11.4%

Quarterly results

Consolidated, ₹ crore · latest reported Mar 26

SalesSelect a row below to chart it

₹ Cr	Mar 25	Mar 26
	15.9	2
	14.6	1.6
	1.3	0.5
	8.1%	22.6%
	0.6	0.2
	0	0
	0.7	0.2
	26.0%	19.8%
	0.5	0.2
	0.21	0.07

Jun 25, Sep 25, Dec 25 not reported by the data source.

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +7.7%
Profit CAGR 3Y: +2.2%
ROE: 1.9%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
99.9	164	129	125
–	+64.5%	minus 21.5%	minus 3.2%
97.5	161	124	121
2.5	3.6	5	3.8
2.5%	2.2%	3.9%	3.0%
−0.1	−0.1	0	0
1	2	1.5	2.3
0	0	0	0
−0.1	−0	–	–
1.4	1.4	3.5	1.4
34.1%	23.8%	25.8%	31.4%
0.9	1.1	2.6	1
–	+19.0%	+142.5%	minus 63.0%
0.76	0.45	1.00	–

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
12	24	24	26.3
12.4	13.5	14.4	36
15.9	19.4	17.2	13.2
37.3	75.9	76.7	130
77.6	133	132	206
0	0	0	0.1
5.7	13.9	0.4	1.2
71.8	119	132	204
77.6	133	132	206

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
−21	−5.4	−9.2	−18.3
−0	−0	−0	−0
26.5	13.6	−4.2	18.8
5.5	8.2	−13.5	0.4
−0	−0	−0	−0
−21	−5.4	−9.2	−18.4

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you